- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00500370
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
19 mars 2015 uppdaterad av: AstraZeneca
This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Faktisk)
163
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Arizona
-
Peoria, Arizona, Förenta staterna
- Research Site
-
Tucson, Arizona, Förenta staterna
- Research Site
-
-
California
-
Santa Ana, California, Förenta staterna
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna
- Research Site
-
-
Kansas
-
Topeka, Kansas, Förenta staterna
- Research Site
-
Wichita, Kansas, Förenta staterna
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Förenta staterna
- Research Site
-
-
Missouri
-
St. Louis, Missouri, Förenta staterna
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna
- Research Site
-
-
South Carolina
-
Goose Creek, South Carolina, Förenta staterna
- Research Site
-
Spartanburg, South Carolina, Förenta staterna
- Research Site
-
-
Texas
-
Dallas, Texas, Förenta staterna
- Research Site
-
San Antonio, Texas, Förenta staterna
- Research Site
-
-
Washington
-
Renton, Washington, Förenta staterna
- Research Site
-
-
-
-
-
Ponce, Puerto Rico
- Research Site
-
San Juan, Puerto Rico
- Research Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Have a Body Mass Index (BMI) >= 30kg/m^2
Exclusion Criteria:
- Have ever participated in this study previously, or any other study using exenatide (AC2993/LY2148568) or GLP-1 analogs
- Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of study start (this criterion includes drugs that have not received regulatory approval for any indication at the time of study entry)
- Diagnosis of diabetes mellitus (other than gestational diabetes), or previous use of anti-diabetic medications for > 3 months
- Have had a change in prescribed lipid-lowering or blood pressure agents within 4 weeks of screening
- Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening
- Are actively participating in, or have participated in a formal weight loss program within the last 3 months
- Have a history of chronic use of drugs that directly affect gastrointestinal motility, including, but not limited to Reglan (metoclopramide) and chronic macrolide antibiotics
- Have been treated with any anti-diabetic medications within 3 months of screening
- Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study start
- Have had bariatric surgery
- Have had an organ transplant
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Grupp A
|
subkutan injektion (5mcg eller 10mcg), två gånger om dagen
Andra namn:
|
Placebo-jämförare: Grupp B
|
subcutaneous injection (equivalent volume to active dose), twice a day
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Body Weight
Tidsram: 24 weeks
|
Change in body weight from baseline after 24 weeks of treatment (i.e., body weight at week 24 minus body weight at week 0)
|
24 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Body Mass Index (BMI)
Tidsram: 24 weeks
|
Change in BMI from baseline after 24 weeks of treatment (i.e., BMI at week 24 minus BMI at week 0)
|
24 weeks
|
Change in Waist-to-hip Ratio
Tidsram: 24 weeks
|
Waist-to-hip ratio at week 24 compared to waist-to-hip ratio at week 0 (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0).
Waist-to-hip ratio equals waist circumference at given time point divided by hip circumference at given timepoint.
|
24 weeks
|
Percentage of Patients Experiencing >=5% Weight Loss
Tidsram: 24 weeks
|
Percentage of exenatide and placebo treated patients experiencing >=5% weight loss after 24 weeks of treatment (i.e., [weight at week 0 minus weight at week 24] divided by weight at week 0 times 100% >=5%)
|
24 weeks
|
Change in Total Cholesterol
Tidsram: 24 weeks
|
Change in total cholesterol from baseline after 24 weeks of treatment (i.e., total cholesterol at week 24 minus total cholesterol at week 0)
|
24 weeks
|
Change in High Density Lipoprotein (HDL) Cholesterol
Tidsram: 24 weeks
|
Change in HDL cholesterol from baseline after 24 weeks of treatment (i.e., HDL cholesterol at week 24 minus HDL cholesterol at week 0)
|
24 weeks
|
Ratio of Endpoint (LOCF) to Baseline for Fasting Triglycerides (Logarithmically Transformed)
Tidsram: 24 weeks
|
Ratio of triglycerides at week 24 compared to triglycerides at week 0 (i.e., triglycerides at week 24 divided by triglycerides at week 0)
|
24 weeks
|
Change in Low Density Lipoprotein (LDL) Cholesterol
Tidsram: 24 weeks
|
Change in LDL cholesterol from baseline following 24 weeks of treatment (i.e., LDL cholesterol at week 24 minus LDL cholesterol at week 0)
|
24 weeks
|
Change in Fasting Serum Glucose
Tidsram: 24 weeks
|
Change in fasting serum glucose from baseline following 24 weeks of treatment (i.e., fasting serum glucose at week 24 minus fasting serum glucose at week 0)
|
24 weeks
|
Change in Serum Glucose AUC Levels Following Oral Glucose Tolerance Test (OGTT)
Tidsram: 24 weeks
|
Change in serum glucose AUC following OGTT (week 24 compared to week 0) (i.e., serum glucose AUC at week 24 minus serum glucose AUC at week 0)
|
24 weeks
|
Ratio of Endpoint (LOCF) to Baseline for Homeostatic Model Assessment-Beta Cell (HOMA-B) (Logarithmically Transformed)
Tidsram: 24 weeks
|
Ratio of HOMA-B at week 24 to HOMA-B at week 0 (i.e., HOMA-B at week 24 divided by HOMA-B at week 0).
HOMA-B is a measure of beta cell function.
|
24 weeks
|
Ratio of Endpoint (LOCF) to Baseline for Homeostatic Model Assessment-Insulin Sensitivity (HOMA-S) (Logarithmically Transformed)
Tidsram: 24 weeks
|
Ratio of HOMA-S at week 24 to HOMA-S at week 0 (i.e., HOMA-S at week 24 divided by HOMA-S at week 0).
HOMA-S is a measure of insulin sensitivity.
|
24 weeks
|
Incidence of Patients That Demonstrate Overt Signs of Diabetes Mellitus Diagnosis
Tidsram: 24 weeks
|
Number of patients in each treatment group that demonstrate overt signs of diabetes mellitus diagnosis by week 24
|
24 weeks
|
Incidence of Patients That Demonstrate Normalization of Impaired Fasting Glucose (IFG) and/or Impaired Glucose Tolerance (IGT)
Tidsram: 24 weeks
|
Number of patients in each treatment group that demonstrate normalization of IFG and/or IGT by week 24
|
24 weeks
|
Change in High Sensitivity C-reactive Protein (hsCRP)
Tidsram: 24 weeks
|
Change in hsCRP levels from baseline following 24 weeks of treatment (i.e., hsCRP at week 24 minus hsCRP at week 0)
|
24 weeks
|
Change in Glycosylated Hemoglobin (HbA1c)
Tidsram: 24 weeks
|
Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)
|
24 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Studierektor: James Malone, MD, Eli Lilly and Company
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juni 2007
Primärt slutförande (Faktisk)
1 februari 2008
Avslutad studie (Faktisk)
1 februari 2008
Studieregistreringsdatum
Först inskickad
10 juli 2007
Först inskickad som uppfyllde QC-kriterierna
10 juli 2007
Första postat (Uppskatta)
12 juli 2007
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
7 april 2015
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
19 mars 2015
Senast verifierad
1 mars 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- H8O-MC-GWBP
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fetma
-
SanionaAvslutadHypothalamic Injury-induced Obesity (HIO)Danmark
Kliniska prövningar på exenatid
-
AstraZenecaEli Lilly and CompanyAvslutadTyp 2-diabetes mellitusFörenta staterna
-
AstraZenecaAvslutadTyp 2-diabetes mellitusKanada, Förenta staterna
-
AstraZenecaEli Lilly and CompanyAvslutadTyp 2-diabetes mellitusKorea, Republiken av, Mexiko, Tyskland, Grekland, Argentina, Indien, Australien
-
University at BuffaloAmylin Pharmaceuticals, LLC.Avslutad
-
AstraZenecaEli Lilly and CompanyAvslutadTyp 2-diabetes mellitusKorea, Republiken av, Kina, Japan, Taiwan, Indien
-
AstraZenecaAvslutadDiabetes mellitus, typ 2Förenta staterna
-
AstraZenecaEli Lilly and CompanyAvslutadTyp 2-diabetes mellitusFörenta staterna
-
AstraZenecaEli Lilly and CompanyAvslutad
-
Metabolic Center of Louisiana Research FoundationAmylin Pharmaceuticals, LLC.AvslutadPolycystiskt ovariesyndromFörenta staterna
-
GlaxoSmithKlineAvslutadDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus